Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.

Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, Wölfler A, Zebisch A, Gerger A, Pristauz G, Petru E, White B, Roberts CES, John JS, Schimek MG, Geigl JB, Bauernhofer T, Sill H, Bock C, Heitzer E, Speicher MR.

Nat Commun. 2019 Oct 11;10(1):4666. doi: 10.1038/s41467-019-12714-4.

2.

The potential of liquid biopsies for the early detection of cancer.

Heitzer E, Perakis S, Geigl JB, Speicher MR.

NPJ Precis Oncol. 2017 Oct 17;1(1):36. doi: 10.1038/s41698-017-0039-5. eCollection 2017. Review.

3.

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.

Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR.

Int J Cancer. 2018 Sep 1;143(5):1236-1248. doi: 10.1002/ijc.31397. Epub 2018 Apr 10.

4.

Single-Stranded DNA Library Preparation Does Not Preferentially Enrich Circulating Tumor DNA.

Moser T, Ulz P, Zhou Q, Perakis S, Geigl JB, Speicher MR, Heitzer E.

Clin Chem. 2017 Oct;63(10):1656-1659. doi: 10.1373/clinchem.2017.277988. Epub 2017 Aug 14. No abstract available.

5.

Patient monitoring through liquid biopsies using circulating tumor DNA.

Ulz P, Heitzer E, Geigl JB, Speicher MR.

Int J Cancer. 2017 Sep 1;141(5):887-896. doi: 10.1002/ijc.30759. Epub 2017 May 25. Review.

6.

A novel mutation in ATRX associated with intellectual disability, syndromic features, and osteosarcoma.

Smolle MA, Heitzer E, Geigl JB, Al Kaissi A, Liegl-Atzwanger B, Seidel MG, Holzer LA, Leithner A.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26522. Epub 2017 Mar 30. No abstract available.

PMID:
28371197
7.

Acute myeloid leukemia with TP53 germ line mutations.

Zebisch A, Lal R, Müller M, Lind K, Kashofer K, Girschikofsky M, Fuchs D, Wölfler A, Geigl JB, Sill H.

Blood. 2016 Nov 3;128(18):2270-2272. Epub 2016 Sep 12. No abstract available.

8.

mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Adv Exp Med Biol. 2016;924:147-155.

PMID:
27753036
9.

Inferring expressed genes by whole-genome sequencing of plasma DNA.

Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB, Heitzer E, Speicher MR.

Nat Genet. 2016 Oct;48(10):1273-8. doi: 10.1038/ng.3648. Epub 2016 Aug 29.

PMID:
27571261
10.

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.

Ulz P, Belic J, Graf R, Auer M, Lafer I, Fischereder K, Webersinke G, Pummer K, Augustin H, Pichler M, Hoefler G, Bauernhofer T, Geigl JB, Heitzer E, Speicher MR.

Nat Commun. 2016 Jun 22;7:12008. doi: 10.1038/ncomms12008.

11.

Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies.

Heitzer E, Ulz P, Geigl JB, Speicher MR.

Mol Oncol. 2016 Mar;10(3):494-502. doi: 10.1016/j.molonc.2015.12.004. Epub 2015 Dec 17. Review.

12.

Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Clin Chem. 2015 Jun;61(6):838-49. doi: 10.1373/clinchem.2014.234286. Epub 2015 Apr 20.

13.

Circulating tumor DNA as a liquid biopsy for cancer.

Heitzer E, Ulz P, Geigl JB.

Clin Chem. 2015 Jan;61(1):112-23. doi: 10.1373/clinchem.2014.222679. Epub 2014 Nov 11. Review.

14.

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.

Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H.

Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.

15.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

16.

Hematogenous dissemination of glioblastoma multiforme.

Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K, Riethdorf S.

Sci Transl Med. 2014 Jul 30;6(247):247ra101. doi: 10.1126/scitranslmed.3009095.

17.

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR.

PLoS Genet. 2014 Mar 27;10(3):e1004271. doi: 10.1371/journal.pgen.1004271. eCollection 2014 Mar.

18.

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

Heitzer E, Lax S, Lafer I, Müller SM, Pristauz G, Ulz P, Jahn S, Högenauer C, Petru E, Speicher MR, Geigl JB.

BMC Med Genet. 2013 Dec 29;14:129. doi: 10.1186/1471-2350-14-129.

19.

Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?

El-Heliebi A, Kroneis T, Zöhrer E, Haybaeck J, Fischereder K, Kampel-Kettner K, Zigeuner R, Pock H, Riedl R, Stauber R, Geigl JB, Huppertz B, Sedlmayr P, Lackner C.

J Transl Med. 2013 Sep 17;11:214. doi: 10.1186/1479-5876-11-214.

20.

Circulating tumor cells and DNA as liquid biopsies.

Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR.

Genome Med. 2013 Aug 23;5(8):73. doi: 10.1186/gm477. eCollection 2013. Review.

21.

Genetic and epigenetic analysis of putative breast cancer stem cell models.

Balic M, Schwarzenbacher D, Stanzer S, Heitzer E, Auer M, Geigl JB, Cote RJ, Datar RH, Dandachi N.

BMC Cancer. 2013 Jul 24;13:358. doi: 10.1186/1471-2407-13-358.

22.

Single circulating tumor cell sequencing for monitoring.

Auer M, Heitzer E, Ulz P, Geigl JB, Speicher MR.

Oncotarget. 2013 Jun;4(6):812-3. No abstract available.

23.

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, Pichler M, Eisner F, Haeusler M, Riethdorf S, Pantel K, Samonigg H, Hoefler G, Augustin H, Geigl JB, Speicher MR.

Genome Med. 2013 Apr 5;5(4):30. doi: 10.1186/gm434. eCollection 2013.

24.

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Cancer Res. 2013 May 15;73(10):2965-75. doi: 10.1158/0008-5472.CAN-12-4140. Epub 2013 Mar 7.

25.

Paraganglioma of the carotid body: treatment strategy and SDH-gene mutations.

Fruhmann J, Geigl JB, Konstantiniuk P, Cohnert TU.

Eur J Vasc Endovasc Surg. 2013 May;45(5):431-6. doi: 10.1016/j.ejvs.2013.01.018. Epub 2013 Feb 19.

26.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Int J Cancer. 2013 Jul 15;133(2):346-56. doi: 10.1002/ijc.28030. Epub 2013 Feb 13.

27.

Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations.

Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Jüttner F, Geigl JB, Speicher MR.

J Clin Oncol. 2012 Nov 10;30(32):e337-40. doi: 10.1200/JCO.2011.41.2965. Epub 2012 Oct 1. No abstract available.

PMID:
23032617
28.

Familial aggregation of urinary tract and bone tumors: searching for a syndrome.

Frings A, Geigl JB, Liegl-Atzwanger B, Leithner A.

Case Rep Med. 2012;2012:107894. doi: 10.1155/2012/107894. Epub 2012 May 20.

29.

High-resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer.

Mathiesen RR, Fjelldal R, Liestøl K, Due EU, Geigl JB, Riethdorf S, Borgen E, Rye IH, Schneider IJ, Obenauf AC, Mauermann O, Nilsen G, Christian Lingjaerde O, Børresen-Dale AL, Pantel K, Speicher MR, Naume B, Baumbusch LO.

Int J Cancer. 2012 Aug 15;131(4):E405-15. doi: 10.1002/ijc.26444. Epub 2011 Nov 9.

30.

Multiple intratumoral KRAS mutations can clonally segregate to different lymph node metastases in colon cancer.

Jahn SW, Winter G, Stacher E, Halbwedl I, Gattenlöhner S, Stockinger R, Spreitzer S, Waldispuehl-Geigl J, Geigl JB, Offner F, Hoefler G.

Histopathology. 2011 Aug;59(2):342-5. doi: 10.1111/j.1365-2559.2011.03902.x. No abstract available.

PMID:
21884216
31.

Combined molecular genetic and cytogenetic analysis from single cells after isothermal whole-genome amplification.

Kroneis T, Geigl JB, El-Heliebi A, Auer M, Ulz P, Schwarzbraun T, Dohr G, Sedlmayr P.

Clin Chem. 2011 Jul;57(7):1032-41. doi: 10.1373/clinchem.2011.162131. Epub 2011 May 10.

32.

Evolution of genomic instability in diethylnitrosamine-induced hepatocarcinogenesis in mice.

Aleksic K, Lackner C, Geigl JB, Schwarz M, Auer M, Ulz P, Fischer M, Trajanoski Z, Otte M, Speicher MR.

Hepatology. 2011 Mar;53(3):895-904. doi: 10.1002/hep.24133.

PMID:
21374661
33.

Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations.

Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, Winter R, Moinfar F.

Histopathology. 2010 Dec;57(6):877-84. doi: 10.1111/j.1365-2559.2010.03724.x.

PMID:
21166701
34.

[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].

Simon K, Geigl JB, Pristauz G.

Wien Med Wochenschr. 2010 Nov;160(19-20):478-82. doi: 10.1007/s10354-010-0831-0. Review. German.

PMID:
20890790
35.

[Hereditary gastric cancer].

Wolf EM, Geigl JB, Svrcek M, Vieth M, Langner C.

Pathologe. 2010 Oct;31(6):423-9. doi: 10.1007/s00292-010-1353-7. German.

PMID:
20824432
36.

Mapping of balanced chromosome translocation breakpoints to the basepair level from microdissected chromosomes.

Obenauf AC, Schwarzbraun T, Auer M, Hoffmann EM, Waldispuehl-Geigl J, Ulz P, Günther B, Duba HC, Speicher MR, Geigl JB.

J Cell Mol Med. 2010 Aug;14(8):2078-84. doi: 10.1111/j.1582-4934.2010.01116.x.

37.

Effect of genome-wide association studies, direct-to-consumer genetic testing, and high-speed sequencing technologies on predictive genetic counselling for cancer risk.

Speicher MR, Geigl JB, Tomlinson IP.

Lancet Oncol. 2010 Sep;11(9):890-8. doi: 10.1016/S1470-2045(09)70359-6. Epub 2010 May 25. Review.

PMID:
20537948
38.

[BRCA1- and BRCA2 mutations: Clinical management of patients with hereditary breast and ovarian cancer].

Pristauz G, Geigl JB, Petru E.

Wien Med Wochenschr. 2010 Apr;160(7-8):158-62. doi: 10.1007/s10354-010-0772-7. Review. German.

PMID:
20473725
39.

Sporadic gastric Peutz-Jeghers polyp with intraepithelial neoplasia.

Harbaum L, Geigl JB, Volkholz H, Schwarzbraun T, Oschmautz H, Vieth M, Langner C.

APMIS. 2009 Dec;117(12):941-3. doi: 10.1111/j.1600-0463.2009.02549.x. No abstract available.

PMID:
20078560
40.

Identification of small gains and losses in single cells after whole genome amplification on tiling oligo arrays.

Geigl JB, Obenauf AC, Waldispuehl-Geigl J, Hoffmann EM, Auer M, Hörmann M, Fischer M, Trajanoski Z, Schenk MA, Baumbusch LO, Speicher MR.

Nucleic Acids Res. 2009 Aug;37(15):e105. doi: 10.1093/nar/gkp526. Epub 2009 Jun 18.

41.

9p21 deletion in primary cutaneous large B-cell lymphoma, leg type, may escape detection by standard FISH assays.

Wiesner T, Obenauf AC, Geigl JB, Vallant EM, Speicher MR, Fink-Puches R, Kerl H, Cerroni L.

J Invest Dermatol. 2009 Jan;129(1):238-40. doi: 10.1038/jid.2008.224. Epub 2008 Aug 14. No abstract available.

42.

Defining 'chromosomal instability'.

Geigl JB, Obenauf AC, Schwarzbraun T, Speicher MR.

Trends Genet. 2008 Feb;24(2):64-9. doi: 10.1016/j.tig.2007.11.006. Epub 2008 Jan 14. Review.

PMID:
18192061
43.

Systemic spread is an early step in breast cancer.

Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA.

Cancer Cell. 2008 Jan;13(1):58-68. doi: 10.1016/j.ccr.2007.12.003.

45.

Multiplex-fluorescence in situ hybridization for chromosome karyotyping.

Geigl JB, Uhrig S, Speicher MR.

Nat Protoc. 2006;1(3):1172-84.

PMID:
17406400
46.

[Genetic counseling in multiple pregnancies].

Uhrig S, Geigl JB, Speicher MR.

Gynakol Geburtshilfliche Rundsch. 2007;47(1):9-13. German.

PMID:
17272932
47.

High resolution array-CGH analysis of single cells.

Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, Carter NP, Speicher MR.

Nucleic Acids Res. 2007;35(3):e15. Epub 2006 Dec 18.

48.

Delineation of a 2q deletion in a girl with dysmorphic features and epilepsy.

Langer S, Geigl JB, Wagenstaller J, Lederer G, Hempel M, Daumer-Haas C, Leifheit HJ, Speicher MR.

Am J Med Genet A. 2006 Apr 1;140(7):764-8.

PMID:
16523518
49.

Live cell catapulting and recultivation does not change the karyotype of HCT116 tumor cells.

Langer S, Geigl JB, Ehnle S, Gangnus R, Speicher MR.

Cancer Genet Cytogenet. 2005 Sep;161(2):174-7.

PMID:
16102590
50.

Sequential application of interphase-FISH and CGH to single cells.

Langer S, Geigl JB, Gangnus R, Speicher MR.

Lab Invest. 2005 Apr;85(4):582-92.

Supplemental Content

Loading ...
Support Center